For adults with Type 2 diabetes mellitus (T2DM) who remain above target on metformin alone, early intensification remains a common clinical challenge. A Phase IV randomized trial published in the Journal of Diabetes reported that a triple fixed-dose combination of glimepiride, voglibose, and extended-release metformin produced larger glycated hemoglobin (HbA1c) reductions than two commonly used dual combinations over 24 weeks.

This open-label, active-controlled study enrolled adults with T2DM inadequately controlled on metformin monotherapy. Of 458 screened patients, 399 were randomized to glimepiride+voglibose+metformin extended-release (n=133), voglibose+metformin (n=135), or glimepiride+metformin (n=131), with all treatments given twice daily. The primary endpoint was change in HbA1c from baseline. Mean baseline HbA1c was approximately 8.35%.

All treatment groups showed significant HbA1c reductions at Weeks 12 and 24. At Week 12, mean HbA1c change was greater with triple therapy versus voglibose+metformin (−1.02% vs −0.68%; p<0.001) and versus glimepiride+metformin (−1.02% vs −0.88%; p=0.0154). At Week 24, reductions remained larger with triple therapy at −1.57%, compared with −1.11% and −1.28%, respectively (p<0.001 and p=0.0002).

Safety findings were favorable across groups. Forty-nine adverse events were reported in 32 of 399 patients (8.0%). One patient in the triple-therapy group and one in the voglibose+metformin group experienced level 1 hypoglycemia that required no management. No severe or serious adverse events occurred.

These findings suggest that in adults with T2DM inadequately controlled on metformin alone, triple fixed-dose oral therapy may offer a more effective intensification option while maintaining acceptable short-term tolerability.